Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Dr Jamaji C. Nwanaji-Enwerem joins Ethics Talk to discuss his collection of images: Intentionally Retained, Intentionally Fragmented, Accidentally Retained, and Accidentally Fragmented.
Using data from comparative effectiveness studies to inform cost-effectiveness analyses or other economic evaluations would strengthen ethical policy making.
AMA J Ethics. 2015;17(7):651-655. doi:
10.1001/journalofethics.2015.17.7.pfor1-1507.
Drivers, physicians, and motor vehicle agencies all have some responsibility in reducing the number of fatal traffic accidents caused by driver sleepiness.
Two bioethicists argue that prenatal disability screening promotes negativity toward the disabled and gives parents the ability to selectively form families.
A philosophy professor argues that prenatal genetic testing allows potentially painful afflictions to be discovered prior to birth and does not unjustly discriminate against disabled people.
Physicians should seriously weigh the benefits and risks involved prior to discussing the possibility of genetic testing with a patient or referring them to a genetic counselor.